Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab
Planning To Leverage Biosimilar Cost Competitiveness After Filings In Korea And US
Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.
